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PEGylation of protein and peptide drugs is frequently used to improve in vivo efficacy. We investigated the action mechanism of tachyplesin I,
a membrane-acting cyclic antimicrobial peptide from Tachypleus tridentatus and the effects of PEGylation on the mechanism. The PEGylated
peptide induced the leakage of calcein from egg yolk L-α-phosphatidylglycerol/egg yolk L-α-phosphatidylcholine large unilamellar vesicles
similarly to the parent peptide. Both peptides induced lipid flip-flop coupled to leakage and was translocated into the inner leaflet of the bilayer,
indicating that tachyplesin I forms a toroidal pore and that PEGylation did not alter the basic mechanism of membrane permeabilization of the
parent peptide. Despite their similar activities against model membranes, the peptides showed very different biological activities. The cytotoxicity
of tachyplesin I was greatly reduced by PEGylation, although the antimicrobial activity was significantly weakened. We investigated the
enhancement of the permeability of inner membranes induced by the peptides. Our results suggested that outer membranes and peptidoglycan
layers play an inhibitory role in the permeation of the PEG moiety. Furthermore, a reduction in DNA binding by PEGylation may also contribute
to the weak activity of the PEGylated peptide.
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Nowadays, a growing number of bacteria showing resistance
to conventional antibiotics and reemerging infectious diseasesAbbreviations:AMEM,Alphamodification of Eagle's medium; C6-NBD-PC,
1-palmitoyl-2-[6-[(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]caproyl]-L-α-phos-
phatidylcholine; CD, circular dichroism; CFU, colony forming unit; CHO,
Chinese Hamster Ovary; DNS-PE, N-(5-dimethylaminonaphthalene-1-sulfonyl)-
1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium salt;
FBS, fetal bovine serum; Fmoc, 9-fluorenylmethoxycarbonyl; HPLC, high-
performance liquid chromatography; L/P, lipid-to-peptide molar ratio; LUVs, large
unilamellar vesicles; MIC, minimal inhibitory concentration; MLVs, multilamellar
vesicles; NAPB, 10 mM sodium phosphate/100 mMNaCl, pH 7.4 buffer; ONPG,
o-nitrophenyl-β-D-galactoside; PC, egg yolk L-α-phosphatidylcholine; PEG,
polyethyleneglycol; PG, L-α-phosphatidyl-DL-glycerol enzymatically converted
from PC; Pyrene-PC, 1-hexadecanoyl-2-(1-pyrenehexanoyl)-sn-glycero-3-phos-
phocholine; SUVs, small unilamellar vesicles; TSB, tryptic soy broth; WST-1, 2-
(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monoso-
dium salt
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doi:10.1016/j.bbamem.2007.01.005become serious problems. Development of therapeutic agents
effective against these bacteria is a pressing need. Antimicrobial
peptides are promising candidates of novel therapeutic agents
[1,2] because of broad antimicrobial spectra and high selective
toxicity. So far, more than 880 antimicrobial peptides have been
isolated from plants, insects, animals including human or
predicted from gene sequences, and considered to play an
important role in innate immunity of their host species [2]. Several
antimicrobial peptides are in clinical trial, however, most of them
are mainly for topical use. There are few antimicrobial peptides
for systemic therapy because of many hurdles to overcome [1].
First, peptide drugs have many disadvantages such as plausible
antigenicity and short circulating half-life due to protease
digestion and rapid kidney clearance [3,4]. In addition to these
general problems, there are many problems specific for
antimicrobial peptides, e.g., low therapeutic indices in vivo
[1,5]. This is partly because of a reduction in activity in the
presence of serum [6,7], plasma [7] or divalent cation [6,8].
Several attempts have been made to improve therapeutic indices.
For example, entrapment of indolicidin in liposome improved the
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liposomes were reported to activate complements and could
damage heart and liver cells [3,10].
On the other hand, attaching a polyethyleneglycol (PEG)
moiety to peptide and protein drugs (PEGylation) is frequently
used to improve in vivo efficacies of these drugs [3].
PEGylation prolongs circulating half-life and eliminating
immunogenicity [3,11]. Despite the usefulness of PEGylation,
there is only one short report about the PEGylation of
antimicrobial peptides [12]. Guiotto et al. conjugated PEG to
nisin to improve the solubility and found that PEGylation
reduced the antimicrobial activity by more than two fold.
Therefore we have almost no information about the effects of
the attached PEG moiety on the activity and the mechanism of
action of the parent antimicrobial peptide.
Tachyplesin I is a representative cyclic β-sheet antimicrobial
peptide isolated from the acid extracts of hemocytes of the
horseshoe crab, Tachypleus tridentatus (Fig. 1) [13]. Our group
has shown that the peptide forms transient pores in membranes
containing acidic phospholipids and translocated across mem-
branes upon pore disintegration [14]. Other groups have studied
membrane permeabilizing activity of the peptide using the
native peptide or analogue peptides [15–17]. However, it is not
clear if tachyplesin I forms a toroidal pore that has been
proposed for other antimicrobial peptides [18,19], because
peptide-induced lipid flip-flop that is characteristic for toroidal
pores has not yet been successfully detected. The peptide also
interacts with DNA [20].
In this study, we attached PEG (M.W.=5000 on average) to
the N-terminus of tachyplesin I (PEG-tachyplesin). We will
compare PEG-tachyplesin and tachyplesin I in terms of
interactions with membranes and DNA, antimicrobial activity
and cytotoxicity against mammalian cells.
2. Materials and methods
2.1. Peptides
PEG-tachyplesin was custom synthesized by Peptide Institute (Minou,
Japan). Tachyplesin I was synthesized by a standard Fmoc-based solid phase
method as described elsewhere [21]. The concentrations of all peptides were
determined on the basis of the UV absorption.
2.2. Liposomes
Egg yolk L-α-phosphatidylcholine (PC) and L-α-phosphatidyl-DL-glycerol
enzymatically converted from PC (PG) were obtained from Sigma (St. Louis,Fig. 1. Amino acid sequences of the peptides used in this study.MO). Calcein was supplied by Dojindo (Kumamoto, Japan). Fluorescent lipids,
N-(5-dimethylaminonaphthalene-1-sulfonyl)-1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine (DNS-PE), 1-palmitoyl-2-[6-[(7-nitrobenz-2-oxa-1,3-dia-
zol-4-yl) amino]caproyl]-L-α-phosphatidylcholine (C6-NBD-PC) and 1-hexade-
canoyl-2-(1-pyrenehexanoyl)-sn-glycero-3-phosphocholine (Pyrene-PC) were
purchased from Molecular Probes (Eugene, OR). All other chemicals were of
special grade and were obtained from Wako (Osaka, Japan).
Large unilamellar vesicles (LUVs) were prepared and characterized, as
previously described elsewhere [22]. Briefly, a lipid film, after being dried under
vacuum overnight, was hydrated with the Tris buffer (10 mMTris/l50 mMNaCl/
1 mMEDTA, pH 7.4) or a 70 mM calcein solution (pHwas adjusted to 7.4 with 1
N NaOH) and vortexed. The suspension was freeze-thawed for 10 cycles to
producemultilamellar vesicles (MLVs). MLVs used in translocation experiments
were freeze-thawed only once to keep the lamellarity larger than 1. MLVs were
then successively extruded through polycarbonate filters (a 100 nm pore size
filter×31 times) to obtain LUVs. Dye-entrapped vesicles were separated from
free calcein on a Bio-Gel A-1.5 m column. The lipid concentration was
determined by phosphorus analysis [23]. LUVs asymmetrically incorporated
Pyrene-PC were prepared for lipid flip-flop experiments [24]. Aliquots of
Pyrene-PC in ethanol were added to a PG/PC LUV suspension at a final ethanol
concentration of 1% (v/v). The LUV suspension was incubated for 30 h with
stirring until Pyrene-PC fluorescence (excited at 341 nm) was stabilized.
2.3. CD spectra
CD spectra were measured on a Jasco J-820 at 30 °C using a 1-mm path-
length quartz cell to minimize the absorbance due to buffer components. Eight
scans were averaged for each sample. The averaged blank spectra (the vesicle
suspension) were subtracted. Spectra of the peptides in the membrane-bound
form were recorded by use of PG/PC (1/1) SUVs. The peptide and the lipid
concentrations were 30 μM and 1.0 mM or 2.0 mM, respectively. The absence of
any optical artifacts was elsewhere confirmed [25].
2.4. Calcein leakage
The release of calcein from the dye-entrapped LUVs was fluorometrically
monitored on a Shimadzu RF-5300 spectrofluorometer at an excitation
wavelength of 490 nm and at an emission wavelength of 520 nm at 30 °C.
For PG/PC LUVs, calcein-free LUVs were mixed with dye-loaded liposomes to
adjust the lipid concentration to the desired value. The maximum fluorescence
intensity corresponding to 100% leakage was determined by addition of 10%
(w/v) Triton X-100 (20 μL) to 2 mL of the sample. The percentage of apparent
leakage value was calculated according to the relationship
% of apparent leakage ¼ 100 ðF  F0Þ=ðFt  F0Þ
where F and Ft are the fluorescence intensity before and after addition of the
detergent, respectively, and F0 represents the fluorescence of intact vesicles.
2.5. Peptide binding
The binding of the peptides to LUVs composed of PG/PC (1/1) was estimated
on the basis of their Trp fluorescence [22]. Peptide solutions (4 μM) were titrated
with a vesicle suspension while the fluorescence spectra of the Trp residue were
recorded after every 30-min incubation for equilibration. Fluorescence data
were averaged for two independent samples after volume correction for dilution
(up to 5%).
2.6. Peptide translocation
Translocation of the peptide into the inner leaflet of the bilayer was
examined by use of MLVs composed of PG/PC/C6-NBD-PC (50/49.5/0.5) [26].
Small aliquots of the MLVs were added to a peptide solution or to a buffer as the
control in the presence of 10 mM sodium dithionite. The fluorescence intensity
of NBD at 530 nm (excitation wavelength is 450 nm) was monitored at 30 °C.
The intensity was represented relative to the value in the absence of the
dithionite ion.
Fig. 2. CD spectra. The CD spectra of the peptides (30 μM) were measured at
30 °C in buffer and in 1 mM PG/PC (1/1) SUVs.
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Lipid flip-flop was assessed according to Müller et al [24]. Pyrene is an
excimer-forming probe and the excimer fluorescence is dependent on the lateral
concentration of the probe [27]. In LUVs asymmetrically labeled with Pyrene-
PC, lipid flip-flop induced by the peptides leads to the dilution of Pyrene-PC as a
result of transbilayer movement, resulting in a decrease in excimer fluorescence
(Ie) and an increase in monomer fluorescence (Im). Asymmetric LUVs were
added to a peptide solution in a quartz cuvette, and the Ie (479 nm) and Im
(397 nm) were recorded (excited at 341 nm). The Ie/Im ratio was used to
calculate the extent of flip-flop [24]. Symmetrically labeled LUVs were also
used to correct the minor effects of the peptides on the Pyrene-PC fluorescence
itself.
2.8. Antimicrobial activity
The minimum inhibitory concentrations (MICs) of the peptides were
determined as described previously [28]. Briefly, Escherichia coli (ATCC
25922) and Staphylococcus epidermidis (ATCC 12228) were cultured in 3%
(w/v) Trypticase soy broth (TSB) at 37 °C for 20 h. To obtain midlogarithmic
phase microorganisms, 1 mL aliquots of the cultures were transferred to 100 mL
of fresh TSB broth and incubated for 2–3 h. The cells were washed with 10 mM
sodium phosphate/100 mMNaCl, pH 7.4 buffer (NAPB) and resuspended in the
same buffer. The cell concentrationswere estimated bymeasuring the absorbance
at 600 nm (ABS600). The relationships between the cell concentration and
ABS600 were predetermined as (CFU/mL=ABS600×3.4×10
8) and (CFU/mL=
ABS600×1.6×10
8) for E. coli and S. epidermidis, respectively. The suspensions
were diluted to 4×105 CFU/mL. The inoculum (90 μL) was added to each
well of 96-well plates. The peptide samples (10 μL) were added to each well
and the plates were incubated at 37 °C for 3 h. TSB [6% (w/v), 100 μL] was
added, and the plates were incubated at 37 °C for 20 h. Cell growth was
assessed by measuring the ABS595 on a model 680 microplate reader (Bio-
Rad, Hercules, CA). MIC was defined as the lowest concentration of the
peptide that inhibited growth. Antimicrobial activities of the peptides were
also assessed in the presence of human serum. The human serum was
extracted from the whole blood of a 25-year-old healthy male. The whole
blood was incubated for 1 h at room temperature and the serum was obtained
by centrifugation. The serum (80 μL) was added to each well of 96-well
plates. After 10 μL of a bacteria solution was added, the total CFU/mL value
was adjusted to be same as assays in the buffer solution. The peptide samples
(10 μL) were added to each well and the antimicrobial activities were
determined as described above.
2.9. Cytotoxicity
2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium,
monosodium salt (WST-1) was obtained from Roche Applied Science
(Mannheim, Germany). Alpha modification of Eagle's medium (AMEM) was
purchased from ICN Biomedicals (Aurora, OH). Cytotoxicities of the peptides
against Chinese Hamster Ovary (CHO)-K1 cells were assessed by the WST-1
assay [29] according to the manufacturer's procedure. The cells (1×104
cells/well) in AMEM containing 10% fetal bovine serum (FBS) were cultured in
96-well microplates and incubated for 12 h under 5% CO2 at 37 °C. After
removal of the medium, the cells were incubated with 100 μL of the peptide
dissolved in the medium (100 μM) for 24 h at 37 °C. Ten microliters of theWST-
1 solution was added, and the cells were further incubated for 1 h. The percent
cell viability was determined by (ABS450–ABS655) for the peptide treated cells/
(ABS450–ABS655) for the untreated cells ×100. All measurements were done at
least in triplicate.
2.10. Inner membrane permeability
o-Nitrophenyl-β-D-galactoside (ONPG) was purchased from Aldrich
(Milwaukee, WI). E. coli ML-35 (i−, y−, z+) strain was used to estimate the
inner membrane permeabilizing activity of the peptides based on the method of
Lehrer [30]. In addition to E. coli ML-35 cells in the midlogarithmic phase,
EDTA-treated cells and spheroplasts were also prepared. To enhance the outermembrane permeability [31], washed midlogarithmic phase bacteria were
incubated with 15 mM EDTA for 15 min. The cells were washed to remove
EDTA, because the entrance of EDTA into the cytosol during the assay affected
β-galactosidase activity controlled by divalent cations [32]. Spheroplasts were
prepared using lysozyme and EDTA [33]. Washed E. coli ML-35 cells were
resuspended in Tris buffer (pH 8.0) containing 0.5 M sucrose. Lysozyme was
immediately added at a final concentration of 20 μg/mL and the cells were
incubated for 10min. After a 1:1 dilution with Tris buffer without sucrose, EDTA
was added at a final concentration of 1 mM and incubated for 15 min. The
formation of spheroplasts was confirmed by osmotic sensitivity [33]. EDTA and
lysozyme were removed by wash. The three types of cells were resuspended in
NAPB and adjusted to an ABS620 value of 0.35 (∼1×108 CFU/mL) [30]. The
cells in 96-well plates were preincubated with ONPG in NAPB containing 1%
TSB (v/v) at 37 °C for 60 min (the preincubation procedure was omitted for
spheroplasts). The peptide solution in NAPB was then added to each well, and
absorbance at 405 nm was measured. The final concentrations of E. coliML-35,
ONPG, and the peptide were 1×107 CFU/mL, 1.67 mM and 2 μM, respectively.
During the inner membrane permeability assay, the viability of bacteria was also
monitored. At various time points, aliquots (10 μL) taken from the sample
solution were immediately diluted into the buffer solution (>100 fold) to stop the
action of the peptides. Aliquots (100 μL) of the diluted solution were seeded on
Luria–Bertani agar plates and the numbers of CFU were counted after 12 h.
2.11. DNA binding assay
Plasmid PET-16b was purchased from Novagen (Madison, WI). Gel
retardation experiments were performed to determine the binding of the peptides
to DNA. The DNA (100 ng, in 10 mM Tris, 1 mM EDTA buffer, pH 8.0) was
mixed with increasing amounts of peptides in 10 μL for 10 min. After adding
2 μL of loading buffer (6× Loading dye, Toyobo, Osaka), the migration of DNA
was assessed by electrophoresis using 0.8% agarose gel in 0.5× Tris borate-
EDTA buffer (45 mM Tris–borate and 1 mM EDTA at pH 8.0) and detected by
the fluorescence of ethidium bromide.
3. Results
3.1. CD spectra
Secondary structures of PEG-tachyplesin were compared to
those of the parent peptide tachyplesin I in buffer and in the
presence of 1 mM PG/PC SUVs (Fig. 2). Because further
addition of SUVs did not change CD spectra (data not shown),
the peptides were completely bound to SUVs. Under both
conditions, CD spectra of the peptides were superimposable,
indicating that the PEGylation did not affect the conformation
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been discussed previously [34].
3.2. Leakage activity
To investigate whether PEGylation alters the activity of the
parent peptide against liposomes or not, we compared the
membrane permeabilizing activities of the peptides. Fig. 3
shows the time course of leakage of the fluorescent dye from
PG/PC and PC LUVs mimicking bacterial and mammalian cell
membranes, respectively. In the PG/PC system (Fig. 3A), the
PEGylated peptide showed almost the same moderate leakage
activity as the parent peptide at a lipid-to-peptide ratio (L/P) of
179. In the PC system, both peptides showed almost no leakage
even at a very low L/P value of 3.7.
3.3. Binding affinity
The binding affinity of the peptides for PG/PC membranes
was estimated on the basis of changes in tryptophan
fluorescence upon binding. Fig. 4 shows the wavelength of
maximal intensity, λmax (A) and the intensity enhancement at
330 nm (B) as a function of L/P. In the absence of liposomes,
PEG-tachyplesin showed a blue shift (∼3 nm) and an enhanced
fluorescent intensity compared to tachyplesin I, suggesting thatFig. 3. Membrane permeabilization activity of the peptides at 30 °C. The percent
leakage value of calcein is plotted as a function of time. (A) PG/PC (1/1) LUVs.
[peptide]=0.4 μM. [lipid]=71.4 μM. (B) PC LUVs. [peptide]=1.0 μM. [lipid]=
3.68 μM.
Fig. 4. Changes in tryptophan fluorescence upon binding to PG/PC (1/1) LUVs
at 30 °C. The wavelength of maximal intensity λmax (A) and the fluorescence
intensity at 330 nm (B) are plotted as a function of L/P ([peptide]=4.0 μM). The
excitation wavelength was 280 nm. Peptides: squares, tachyplesin I; circles,
PEG-tachyplesin.the tryptophan residue of PEG-tachyplesin was located in a
more hydrophobic environment by interacting with the PEG
moiety. The addition of LUVs caused similar blue shifts and
intensity enhancements, indicating that both peptides located at
similar depths in the membranes. The binding of tachyplesin I
was obviously saturated at lower L/P values than that of PEG-
tachyplesin, suggesting the higher binding affinity of tachyple-
sin I. However, both peptides were completely bound to PG/PC
membranes at L/P=179 in the leakage experiments.
3.4. Peptide translocation
In the conventional methods [35], peptides remaining outer
leaflets should be extracted by addition of excess vesicles. This
method did not work because the rates of transfer to additional
PG SUVs were very different between the peptides. Therefore,
the MLV method [26] was used instead to estimate the
translocation of the peptides across lipid bilayers. (Fig. 5).
The addition of the reducing ion dithionite to MLVs containing
NBD-PC reduced the NBD moieties exposed to the external
aqueous phase, making them nonfluorescent. The fluorescence
decrease, corresponding to the fraction of the chromophores on
the MLV surface, was about 15%, indicating that the lamellarity
of the vesicles is larger than 3. If the peptides permeabilize only
Fig. 5. Detection of translocation of the peptides at 30 °C. Small aliquots of
MLVs composed of PG/PC/C6-NBD-PC (50/49.5/0.5) were injected into a
buffer or a peptide solution in the presence of 10 mM sodium dithionite. The
fluorescence (excitation at 450 nm, emission at 530 nm) was normalized to the
intensity in the absence of the quencher. The calculated trace is the curve in the
case of no translocation. [lipid]=100 μM.
Fig. 6. Lipid flip-flop and calcein leakage induced by tachyplesin I (A) and PEG-
tachyplesin (B) at 30 °C. In the flip-flop experiments, asymmetrically labeled
PG/PC/Pyrene-PC (51/45.9/3.1 in the outer leaflet) LUVs were injected into a
peptide solution. Lipid flip-flop induced by the peptide redistributed Pyrene-PC
between the two leaflets, changing the excimer-to-monomer fluorescence ratio.
The %flip-flop value (gray curves) was calculated according to Müller et al (24)
from the ratio. Calcein leakage (black curves) was also determined using LUVs
asymmetrically labeled with Pyrene-PC. [peptide]=0.4 μM. [lipid]=71.4 μM.
Table 1
MICs of the peptides (μM)
E. coli
(ATCC25922)
(+ serum) S. epidermidis
(ATCC12228)
Tachyplesin I 0.5 (2.0) 1.0
PEG-tachyplesin 32 (64) 32
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can react with the NBD moieties facing the first interlamellar
space, resulting in quenching of less than 45%. The expected
time course of quenching in this case is shown as the calculated
curve in Fig. 5. In contrast, if the peptide translocates, the
peptide can permeabilize not only the outermost bilayers but
also the inner bilayers, resulting in quenching of more than
45%. In this case, experimental quenching curves should be
below the calculated curve. The quenching curves of the parent
and the PEGylated peptides were below the calculated curve at
concentrations of 2.0 μM and 6.0 μM, respectively, indicating
that the peptides can translocate across bilayers. It should be
noticed that these experiments can only examine qualitatively
whether a peptide can translocate or not.
3.5. Lipid flip-flop
We assessed lipid flip-flop induced by the peptides using
excimer-forming Pyrene-PC as described by Müller et al. [24]
instead of using a combination of NBD-PC and dithionite ions
[36] because it was impossible to completely stop the
membrane permeabilizing activity of the peptides. Asymme-
trically labeled PG/PC/Pyrene-PC (51/45.9/3.1 in the outer
leaflet) LUVs were injected into a peptide solution. The
peptides decreased Ie and increased Im, indicating that the
peptides induced transbilayer movement of lipids. The percent
flip-flop values were calculated from using the Ie/Im values
and are shown in Fig. 6A for the parent peptide and in Fig.
6B for the PEGylated peptide. Calcein leakage activities were
also determined under the same conditions using asymme-
trically labeled vesicles in the presence of 1% ethanol.
Leakage and lipid flip-flop were almost coupled for both
peptides.
3.6. Biological activities
Table 1 summarizes the MIC values of PEG-tachyplesin and
tachyplesin I against Gram-negative E. coli and Gram-positiveS. epidermidis. The PEGylated peptide showed 64-fold and
32-fold weaker antimicrobial activity against E. coli against S.
epidermidis, respectively, than the parent peptide. Many reports
have showed that blood components inhibit activities of
antimicrobial peptides [6,7]. We also determined MICs of the
peptides in the presence of human serum (Table 1). The
coexistence of serum decreased the antimicrobial activities by 4
fold and 2 fold for tachyplesin I and PEG-tachyplesin,
respectively, indicating PEGylation reduced interaction of
tachyplesin with serum components.
We then assessed cytotoxicities of the peptides against CHO-
K1 cells (Fig. 7). The LD50 value for tachyplesin I was around
Fig. 7. Cytotoxicities of tachyplesin I (square), PEG-tachyplesin (circle) against
CHO-K1 cells assessed by the WST-1 assay.
1165Y. Imura et al. / Biochimica et Biophysica Acta 1768 (2007) 1160–116940 μM. In contrast, PEG-tachyplesin was far less toxic. A
viability of ∼80% was maintained even at 100 μM.
3.7. Inner membrane permeability
In liposomal studies, the PEGylated and the non-PEGylated
peptides showed similar leakage activities, however, theFig. 8. Inner membrane permeabilization against E. coli ML-35 at 25 °C.
Absorbances at 405 nm of tachyplesin I- (open square), PEG-tachyplesin- (open
circle) and buffer- (open triangle) treated cells are shown as a function of time.
[peptide]=2.0 μM. (A) Normal cells (solid curve) and EDTA-treated cells
(dotted curve) (B) Spheroplasted cells. The viability of bacteria (CFU/mL) is
also shown by corresponding filled symbols in (A).PEGylated peptide showed much weaker antimicrobial
activity. To investigate why antimicrobial activity was
decreased by PEGylation, we compared the inner membrane-
permeabilizing activity of PEG-tachyplesin with that of
tachyplesin I using E. coli ML-35 cells which lack lactose
permease necessary for the uptake of ONPG. If the peptide
induces the permeabilization of inner membranes, ONPG
enters the cytoplasm and is degraded by β-galactosidase,
producing o-nitrophenol that shows absorbance at 405 nm
(Fig. 8). The PEGylated peptide induced a slight inner
membrane permeabilization only after a lag time of 60 min
and did not decrease the viability of bacteria for at least 30 min
(Fig. 8A). In contrast, tachyplesin I induced a rapid increase in
the permeability of inner membranes, concomitant with a rapid
decrease in viability (Fig. 8A). To assess influences of outer
membranes on the membrane-permeabilizing activity of the
PEGylated peptide, we also carried out ONPG assay againstFig. 9. Gel retardation assay. Various amounts of tachyplesin I (A) and PEG-
tachyplesin (B) were incubated with 100 ng of plasmid DNA pET-16b, and
DNA binding was assessed by the inhibition of the electrophoretic migration of
DNA by the peptide. The peptide-to-DNAweight ratio is indicated above each
lane. The weight of PEG-tachyplesin is the reduced weight to the tachyplesin
moiety.
Fig. 10. Schematic illustration of the toroidal pore model for tachyplesin I and
PEG-tachyplesin. The peptide molecules first bind to the outer leaflet of the
bilayer membrane. Together with several surrounding lipids, the peptides form a
membrane-spanning pore which allows not only the ion transport but also the
rapid flip-flop of the membrane lipids. Upon the disintegration of the pore, a
fraction of the peptide molecules stochastically translocates into the inner leaflet.
Only PEG-tachyplesin is shown for clarity.
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negative bacteria to polycationic antibiotics by removing divalent
cations that stabilize outer membranes of bacteria [31]. The
EDTA treatment enhanced the permeabilization of inner
membranes and shortened the lag phase (Fig. 8A), indicating
that outer membranes constitute a barrier for the permeation of
the PEGylated peptide. However, another barrier should exist
because the enhanced permeability of inner membranes by the
EDTA treatment was still much smaller than that of the parent
peptide. Therefore, we assessed the permeabilization of inner
membranes by the peptides using spheroplasts of E. coli ML-35
(Fig. 8B). PEG-tachyplesin induced permeabilization comparable
to (about half) that by tachyplesin I. The difference may be due
to the weaker binding of the PEGylated peptide. The
absorbances at 405 nm for spheroplasted cells were lower than
those of intact cells. The EDTA treatment might lower β-
galactosidase activity by chelating divalent cations [32] or β-
galactosidase might be released from cells and removed by
washing during spheroplasting process.
3.8. DNA binding
Yonezawa et al. reported that tachyplesin I binds to DNA
[20]. Gel retardation assay was performed to investigate
whether PEGylation affects the DNA binding ability of the
parent peptide or not (Fig. 9). Tachyplesin I and the PEGylated
peptide inhibited the electrophoretic migration of DNA at a
peptide-to-DNA weight ratio of 2 and 4, respectively(Fig. 9),
indicating that PEGylation lowered the binding affinity for
DNA. Tachyplesin I appears to inhibit the intercalation of
ethidium bromide to DNA at higher peptide-to-DNA ratios
above 8 (Fig. 9B), suggesting a higher binding affinity of
tachyplesin I.
4. Discussion
4.1. Mechanism of membrane permeabilization by tachyplesin I
The mechanism by which tachyplesin I induces membrane
permeabilization is not fully understood. We have previously
shown that the peptide forms an anion selective pore in planar
lipid bilayer and triggers the leakage of calcein from
liposomes, the latter being coupled to the translocation of
the peptide across lipid bilayers [14]. In this study, we
successfully detected tachyplesin-induced lipid flip-flop that
was coupled to calcein leakage (Fig. 6A). These results
indicate that tachyplesin I forms a toroidal pore composed of
peptides and lipids similarly to magainin 2 [36,37], MSI-78
[38], and LL-37 [39] (Fig. 10). The toroidal pore-forming
peptides impose positive curvature strain on lipid bilayers,
and the presence of negative curvature-inducing lipids, such
as phosphatidylethanolamine, suppresses the formation of
toroidal pores [40]. Indeed, the incorporation of phosphati-
dylethanolamine inhibited pore formation [14]. Recently, a
related peptide polyphemusin I was reported to show opposite
effects, i.e. the peptide imposes negative curvature strain on
membranes [41].4.2. Effect of PEGylation on tachyplesin–membrane interactions
The significant conformational change of tachyplesin I upon
the transfer from aqueous phase to membrane-mimetic micelles
has been investigated in detail by NMR [42]. Judged from CD
spectra, PEGylation did not alter secondary structures of
tachyplesin I in solution as well as in membranes, although
fluorescence spectra showed some direct interaction of the PEG
moiety with the Trp residue near the N-terminus in solution
(Fig. 4). It was also reported that PEGylation did not alter
secondary structure of insulin [43].
The binding affinity of the PEGylated peptide for PG/PC
membranes was weaker than the parent peptide (Fig. 4).
Binding of a peptide to membranes are mainly driven by
hydrophobic and electrostatic interactions. The free energy gain
due to hydrophobic interaction is smaller for the PEGylated
peptide because the peptide moiety in solution is already in a
slightly hydrophobic environment. Electrostatic attraction
between the positively charged peptide and the negatively
charged membranes may be also weakened by PEGylation.
PEGylation was reported to reduce the surface charge of a
DNA/PEGylated ployethyleneimine complex [44]. Further-
more, several studies using the surface plasmon resonance
technique showed that PEGylation generally decreases the
target association of native proteins [45–47].
Surprisingly, the attachment of the large PEG moiety (5 kDa)
to the smaller parent peptide (2.3 kDa) neither deteriorates the
intrinsic leakage activity upon complete membrane binding
(Fig. 3A) nor change the mode of action (Fig. 6). The PEG
chain appears not to clog the pore. In contrast, the translocation
efficiency estimated by the MLV method was lowered by
PEGylation (Fig. 5). The efficiency of NBD quenching depends
on several factors other than the translocating activity, i.e., the
binding affinity of each peptide for membranes and the mem-
1167Y. Imura et al. / Biochimica et Biophysica Acta 1768 (2007) 1160–1169brane permeabilization activity. Since the membrane permea-
bilizing activity of the two peptides against PG/PC was almost
the same, the apparent reduced translocation ability of PEG-
tachyplesin is at least partly due to the smaller binding affinity
(Fig. 4). The L/P value for the outermost bilayers was smaller
than 15.
4.3. Effect of PEGylation on biological activities
Tachyplesin I showed cytotoxicity against CHO-K1 cells in
the concentration range of 25 to 100 μM, although the peptide
did not induce the permeabilization of zwitterionic PC bilayers, a
model of mammalian plasma membranes (Fig. 3B). A correla-
tion between PC-permeabilization activity and hemolytic
activity as a measure of cytotoxicity has been reported to for
various peptides [48]. Accumulating evidence suggests that the
negatively charged extracellular matrix such as heparan sulfate
which is lacking in erythrocytes plays an important role in the
interaction of cationic peptides with cells [49–51].
The PEGylation significantly reduced the cytotoxicity of
tachyplesin I (Fig. 7). The charge-masking effect may contribute
to the diminished toxicity. It is also possible that PEG-
tachyplesin could not permeate extracellular matrix efficiently
due to larger steric hindrance of the PEG moiety, as indicated in
ONPG assay using spheroplasted bacteria (Fig. 8B).
The membrane permeabilizing activity appears to primarily
contribute to the bacterial killing activity of tachyplesin I,
because the inner membrane permeabilization was coupled to
the bacterial killing (Fig. 8A). These results are in accordance
with our previous study showing the coupling between
potassium ion efflux from bacteria and decrease in cell viability
[52]. Antimicrobial activity was greatly reduced by PEGylation
(Table 1). The decrease in antimicrobial activity is ascribable to
the loss of inner membrane permeabilizing activity by PEGyla-
tion (Fig. 8A). The two peptides have almost the same
membrane permeabilizing activities against PG/PC LUVs
mimicking bacterial membranes (Fig. 3A), however, the
PEGylated peptide showed significantly lower antimicrobial
activities against both Gram-positive and -negative bacteria than
the parent peptide (Table 1). The largest difference between
LUVs and bacteria is the presence of outer membranes and
peptidoglycan layers. The EDTA treatment slightly increased
the susceptibility to the PEGylated peptide (Fig. 8A), suggesting
the involvement of outer membranes in the protecting effect on
the permeation of the PEGylated peptide. The EDTA and
lysozyme treatment, i.e., spheroplasting significantly increased
the susceptibility to the PEGylated peptide. The PEGylated
peptide induced inner membrane permeabilization comparable
to that of the parent peptide (Fig. 8B). These results suggest that
peptidoglycan layers serve as a major barrier against the
permeation of the PEG moiety. Indeed, a previous study using
Gram-positive Bacillus megaterium shows that the uptake of
PEG molecules (4.5–6.8 kDa) into cells is only about 20% of
that of tritiated water [53]. Our conclusion is reasonable because
peptidoglycan layers are present in both Gram-positive and
-negative bacteria and the PEGylated peptide showed lower
antimicrobial activities against both types of bacteria (Table 1).The diminished binding to DNA (Fig. 9) may also contribute
to the reduction of antimicrobial activity upon PEGylation,
although we showed that the membrane is the primary target of
tachyplesin I. The binding site of tachyplesin I was reported to
be the minor groove [20]. The weaker binding affinity of PEG-
tachyplesin to DNA may be ascribable to the fact that the
standard width (∼0.6 nm) of the minor groove [54] is smaller
than the size of the PEG moiety ( ∼2 nm [55]).
5. Conclusion
We examined the effects of PEGylation on the mechanism of
action of an antimicrobial peptide using tachyplesin I in detail for
the first time. Tachyplesin I was found to form a toroidal pore
similarly to magainin 2. The attachment of the large PEG moiety
(5 kDa) did not change the essential mode of action of the peptide
against lipid bilayers, although the binding affinity was reduced
by 2–3 fold. The PEGylation significantly reduced cytotoxicity,
however, the antimicrobial activity was also reduced at the same
time, because peptidoglycan layers mainly act as a permeation
barrier. Although the membrane is the primary target of
tachyplesin I in bacterial killing, reduced DNA binding may
also contribute to the diminished antimicrobial activity.
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